---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-019682"
form_type: "8-K"
ticker: "DSGN"
cik: "0001807120"
company_name: "Design Therapeutics, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:45:34.949336+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Design Therapeutics reports Q1 2023 net loss of $19.3M; cash $315.4M; Phase 1 MAD data for DT-216 expected in Q3 2023

## Summary
- Net loss of $19.3M for Q1 2023; R&D expenses $15.7M, G&A expenses $5.9M.
- Cash, equivalents and marketable securities $315.4M, expected to fund operations through 2025.
- Initial Phase 1 multiple-ascending dose trial data for DT-216 in Friedreich ataxia expected Q3 2023.
- IND submission for DT-168 eye drop for FECD on track for H2 2023; preclinical data presented at ARVO 2023.
- IND submission for DM1 GeneTAC program on track for H2 2024; development candidate selection underway.

## SEC filing metadata
- accession: 0000950170-23-019682
- form_type: 8-K
- ticker: DSGN
- cik: 0001807120
- company_name: Design Therapeutics, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1807120/000095017023019682/0000950170-23-019682-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1807120/000095017023019682/dsgn-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-019682
- JSON: https://secwatch.observer/filing/0000950170-23-019682.json
- Plain text: https://secwatch.observer/filing/0000950170-23-019682.txt

## Key facts
- Earnings Releases
  Design Therapeutics, Inc. reported financial results for for the quarter ended March 31, 2023.
  - Period: for the quarter ended March 31, 2023
  - Result: reported results
  source text: Research and development (R&D) expenses were $15.7 million for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1807120/000095017023019682/0000950170-23-019682-index.htm
- Earnings Releases
  Design Therapeutics, Inc. reported financial results for for the quarter ended March 31, 2023.
  - Period: for the quarter ended March 31, 2023
  - Result: reported results
  source text: General and administrative (G&A) expenses were $5.9 million for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1807120/000095017023019682/0000950170-23-019682-index.htm
- Earnings Releases
  Design Therapeutics, Inc. reported for the three months ended March 31, 2023 results: net income Net loss was $19.3 million for the quarter ended March 31, 2023..
  - Period: for the three months ended March 31, 2023
  - Net income: Net loss was $19.3 million for the quarter ended March 31, 2023.
  - Result: reported results
  source text: Net loss was $19.3 million for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1807120/000095017023019682/0000950170-23-019682-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.